mRNA COVID Vaccine Dosing Intervals May Be Extended To Mitigate Myocarditis Risk
While data suggests higher risk of myocarditis in young males receiving Moderna’s vaccine, US CDC advisory committee did not consider preferential recommendation. ACIP voted to recommend Spikevax for those 18 years and older following full FDA approval.
You may also be interested in...
All Myocarditis, Pericarditis Cases With COVID-19 Vaccines Now Must Be Reported To VAERS
The change to three vaccine emergency use authorizations was made quietly, most recently for the Novavax vaccine.
COVID-19 Vaccine Dosing Interval Studies Advocated By US FDA, ACIP
FDA’s Doran Fink and CDC’s ACIP members say vaccine manufacturers could conduct a study to determine whether longer intervals between doses would provide greater effectiveness and longer durability. Right now, they are relying on international data.
Moderna’s Vaccine Gets Panel Nod In Adolescents, Older Children; Committee Already Eyes Booster
US FDA advisory committee members debate how a third dose, or booster, of the COVID vaccine should fit into the mix of an EUA expansion for the 12-17 and 6-11 groups; Moderna expects to have immunogenicity and safety data on booster doses in both of age groups by mid-July.